The only curative therapy for many endstage diseases is allograft organ transplantation. Due to the limited supply of donor organs, relatively few patients are recipients of a transplanted organ. Therefore, new strategies are warranted to address this unmet need. Using gene editing technologies, somatic cell nuclear transfer and human induced pluripotent stem cell technologies, interspecies chimeric organs have been pursued with promising results. In this review, we highlight the overall technical strategy, the successful early results and the hurdles that need to be addressed in order for these approaches to produce a successful organ that could be transplanted in patients with endstage diseases.
Bibliographical noteFunding Information:
This work was supported by the NIH (HL144582 and HL160476), RMM (101617-DS-003) and DOD. The authors acknowledge the efforts of Cynthia Faraday for figure preparation.
Copyright © 2022 Choe, Sorensen, Garry and Garry.
- blastocyst complementation
- somatic cell nuclear transfer
PubMed: MeSH publication types
- Journal Article